ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Clinical Characteristics Of Serologic Non-responders To Covid-19 Booster Vaccination In A Cohort Of Solid Organ Transplant Recipients.

F. N. Zervou1, K. Khalil1, T. Lao1, D. Wood2, S. Jonche1, A. Mattoo1

1Transplant Institute, NYU Langone Health, New York, NY, 2New York University Langone Health, Brooklyn, NY

Meeting: 2022 American Transplant Congress

Abstract number: 9064

Keywords: COVID-19, Immunosuppression, Kidney transplantation, Vaccination

Topic: Basic & Clinical Science » Basic & Clinical Science » 73 - COVID-19

Session Information

Session Name: COVID-19

Session Type: Poster Abstract

Date: Sunday, June 5, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: The purpose of this study was to assess the clinical characteristics of serologic non-responders to COVID-19 booster vaccination in a cohort of solid organ transplant recipients.

*Methods: All solid organ transplant recipients our center who received COVID-19 booster vaccination and had SARS-CoV-2 Spike IgG antibodies checked at least 4 weeks after the dose were included. We evaluated the patients who were found to have negative SARS-CoV-2 Spike IgG antibodies despite booster vaccination (i.e. serologic non-responders).

*Results: Among 657 solid organ transplant patients who had received a booster COVID-19 vaccination, 168 patients had Spike IgG antibodies checked during the study period. Forty-nine patients (29.2%) were found to be seronegative and were included in the analysis. 69% were male with a median age of 60 years. The majority of the cohort (47%) were kidney transplant recipients who had received primary vaccination series at a median of 206 days post-transplant. 65% had received basiliximab for induction immunosuppression. Most of the patients (65%) received primary vaccination with Pfizer COVID-19 vaccine and 67% received Pfizer COVID-19 booster vaccination at a median of 187 days after primary vaccination series. Spike IgG antibodies were checked at a median of 41 days from booster vaccination. No patients received rATG within 90 days of booster administration. Similarly, no patients received high dose (>250mg methylprednisolone equivalent) steroids within 30 days prior to booster vaccination. For immunosuppression, 27% were maintained on belatacept and 82% were on anti-metabolites at the time of the booster vacciantion. Ten patients (20%) experienced a COVID-19 infection post-completion of their booster vaccination.

Booster Non-responders (N=49)
Age in Years at Booster? (median, IQR) 60.5 (55-68)
Males (n, %) 34 (69)
Race (n, %)
Caucasian 16 (33)
Black 24 (49)
Asian 3 (6)
Other 6 (12)
Transplant type (n, %)
Kidney 23 (47)
Liver 1 (2)
Heart 11 (22)
Lung 12 (25)
Dual organ 2 (4)
Induction agent (n, %)
Basiliximab 32 (65)
Anti-thymocyte globulin (rATG) 11 (23)
Steroids alone 6 (12)
Vaccine type (n, %)
Pfizer 32 (65)
Moderna 16 (33)
Jansen 1 (2)
Days post-transplant (median, IQR) 206 (133-537)
Booster type (n, %)
Pfizer 33 (67)
Moderna 16 (33)
Days post-transplant (median, IQR) 397 (284-735)
Days between primary series and booster vaccination (median, IQR) 187 (147-193)
Days between booster vaccination and Spike IgG antibody testing (median, IQR) 41 (30-64)
Maintenance Immunosuppression
Belatacept (n, %) 13 (27)
Anti-metabolite (n, %) 40 (82)
COVID-19 Infection (n, %) 10 (20)

*All data is reported as median (IQR) unless otherwise noted

*Conclusions: In our solid organ transplant cohort, the majority of serologic non-responders underwent basiliximab induction and were on an antimetabolite for maintenance immunosuppression. A limitation of our study was the use of different laboratory assays for determining IgG levels. Future work includes evaluating the clinical characteristics of COVID 19 booster serologic responders and comparing the two populations.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Zervou FN, Khalil K, Lao T, Wood D, Jonche S, Mattoo A. Clinical Characteristics Of Serologic Non-responders To Covid-19 Booster Vaccination In A Cohort Of Solid Organ Transplant Recipients. [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/clinical-characteristics-of-serologic-non-responders-to-covid-19-booster-vaccination-in-a-cohort-of-solid-organ-transplant-recipients/. Accessed June 7, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences